Kiora Pharmaceuticals (NASDAQ: KPRX) has reported that its novel ion channel modulator, KIO-300, successfully suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model, according to preclinical data presented at the Epilepsy Foundation Pipeline Conference held June 18-19, 2026, in Leesburg, VA. The findings, showcased in a poster presentation, highlight a significant reduction in epileptiform activity, indicating that KIO-300 may have therapeutic potential beyond its current development focus.
KIO-300 is the active pharmaceutical ingredient of KIO-301, which is the subject of Kiora's ongoing Phase 2 clinical program for vision restoration in patients with gene mutation-agnostic retinitis pigmentosa. The company's ion channel modulator platform is designed to target critical pathways underlying retinal diseases, but the latest data suggest broader applications in neurology. The ability to suppress seizure activity in a TLE model opens avenues for Kiora to explore additional indications for its ion channel modulators.
Dr. Brian M. Strem, Chief Scientific Officer of Kiora Pharmaceuticals, stated, "These preclinical results are encouraging and demonstrate the potential of our ion channel modulator platform to address neurological conditions beyond vision restoration." The company plans to further investigate KIO-300 and related compounds for epilepsy and other central nervous system disorders.
The Epilepsy Foundation Pipeline Conference serves as a platform for showcasing emerging therapies for epilepsy, and Kiora's presentation underscores the potential of small molecule ion channel modulators in treating seizure disorders. Temporal lobe epilepsy is one of the most common forms of epilepsy, often resistant to existing medications, highlighting the need for novel treatments.
Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing advanced therapies for retinal disease. Its lead candidate, KIO-301, is a molecular photoswitch that aims to restore vision in patients with inherited or age-related retinal degeneration, including retinitis pigmentosa, choroideremia, and Stargardt disease. Another candidate, KIO-104, is a next-generation inhibitor of dihydroorotate dehydrogenase (DHODH) for macular edema due to retinal inflammation.
These findings are based on ex vivo studies and do not guarantee success in human clinical trials for epilepsy. However, they represent a strategic expansion of Kiora's pipeline into neurology, potentially increasing the value of its ion channel modulator platform. The company will need to conduct further preclinical and clinical studies to validate these results and determine the safety and efficacy of KIO-300 in epilepsy patients.
The announcement comes as Kiora continues to advance its core programs in ophthalmology. Investors and researchers will be watching closely for updates on both the vision restoration and epilepsy initiatives. The company expects to provide further details on its development plans in upcoming quarters.
